- Home
- / TransMedics
TransMedics
Stock Price
$88.5
2024-10-29
Market Capitalization
$2.9 B
2024-10-29
Revenue
$605.5 M
FY, 2025
TransMedics Summary
Company Summary
- Overview
- TransMedics is a medical device company. It develops organ transplant technologies. The Company provides a warm blood perfusion system that allows for a living organ transplant.
- Type
- Public
- Status
- Active
- Founded
- 1998
- HQ
- Andover, MA, US | view all locations
- Website
- https://www.transmedics.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Stephen Gordon, Chief Financial Officer
John Carey, Vice President of Operations
Miriam Provost, Vice President of Global Regulatory Affairs
LocationsView all
1 location detected
Andover, MA HQ
United States
200 Minuteman Rd
TransMedics Financials
Summary Financials
- Revenue (Q1, 2026)
- $173.9M
- Gross profit (Q1, 2026)
- $101.2M
- Net income (Q1, 2026)
- $7.3M
- Cash (Q1, 2026)
- $461.7M
- EBIT (Q1, 2026)
- $13.3M
- Enterprise value
- $3.3B